Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China *Authors contributed equally.
Int J Biol Markers. 2020 Sep;35(3):90-101. doi: 10.1177/1724600820926172. Epub 2020 Oct 19.
We aimed to determine whether single nucleotide polymorphisms in the gene are related to the response and adverse events of patients receiving neoadjuvant therapy and to explore the mechanism.
Nine single nucleotide polymorphisms of were selected and tested among patients before neoadjuvant therapy. Four models were used in single nucleotide polymorphism genotype analysis: the addictive model compared TT vs TA vs AA; the dominant model compared TT vs TA+AA; the recessive model compared TT+TA vs AA; and the over-dominant model compared TT+AA vs TA (A as the minor allele). We analyzed the associations between single nucleotide polymorphism genotypes and pathological complete response, disease-free survival, and adverse events. Overexpression of the targeted microRNA was carried out using microRNA mimics. Logistic regression was used to analyze the associations between different single nucleotide polymorphism genotypes and pathological complete response outcome. Kaplan-Meier plots and log-rank tests were used to compare disease-free survival between groups with different single nucleotide polymorphism genotypes. The Cox proportional hazards model was used to calculate the adjusted hazard ratio. The Spearman's correlation test was used to determine the correlations between different genotypes and adverse events.
rs4143815C>G was associated with better pathological complete response in the addictive and over-dominant models and with poorer disease-free survival in the recessive model. Patients with different genotypes had different adverse events. Overexpression of miR34c resulted in the downregulation of PD-L1 mRNA expression.
The single nucleotide polymorphism rs4143815 was associated with the pathological complete response rate, disease-free survival, and adverse events in breast cancer patients receiving neoadjuvant therapy. The interaction between miR34c and might be affected by rs4143815.
本研究旨在确定基因中的单核苷酸多态性是否与接受新辅助治疗的患者的反应和不良事件相关,并探讨其机制。
在新辅助治疗前,对患者的基因中的 9 个单核苷酸多态性进行了检测。单核苷酸多态性基因型分析采用了 4 种模型:相加模型比较 TT 与 TA 与 AA;显性模型比较 TT 与 TA+AA;隐性模型比较 TT+TA 与 AA;超显性模型比较 TT+AA 与 TA(A 为次要等位基因)。我们分析了单核苷酸多态性基因型与病理完全缓解、无病生存和不良事件之间的相关性。采用 microRNA 模拟物进行靶向 microRNA 的过表达。采用逻辑回归分析不同单核苷酸多态性基因型与病理完全缓解结局之间的关系。采用 Kaplan-Meier 图和对数秩检验比较不同单核苷酸多态性基因型组之间的无病生存率。采用 Cox 比例风险模型计算调整后的危险比。采用 Spearman 相关检验分析不同基因型与不良事件之间的相关性。
rs4143815C>G 在相加和超显性模型中与更好的病理完全缓解相关,在隐性模型中与更差的无病生存相关。不同基因型的患者有不同的不良事件。miR34c 的过表达导致 PD-L1mRNA 表达下调。
基因的单核苷酸多态性 rs4143815 与接受新辅助治疗的乳腺癌患者的病理完全缓解率、无病生存和不良事件相关。miR34c 和之间的相互作用可能受 rs4143815 的影响。